Reports Q3 revenue $8.365M vs $24.200M last year. Ted Karkus, ProPhase Lab’s Chief Executive Officer, commented, “Q3 represented another positive step in the Company’s transformation from a business focused on Covid testing to a diversified healthcare technology company with multiple subsidiaries. We believe but cannot assure that several of our wholly owned subsidiaries have the potential to each attain a valuation which would exceed the entire current market cap of the Company.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRPH:
- ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time
- ProPhase Labs announces growth expectations for Pharmaloz
- ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output.
- DSS CEO looking forward to ‘significant growth’ for remainder of the year
- ProPhase Labs to Present at The ThinkEquity Conference
